Unknown

Dataset Information

0

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review.


ABSTRACT:

Background

Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety.

Methods

MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20th June 2020.

Results

We identified 3 indirect pre-clinical studies and 28 clinical studies including 5776 patients with COVID-19 (13 with a comparison group, 15 single-arm). To date, no randomized trials have been published. We retrieved no studies at low risk of bias. Forty-five ongoing studies were retrieved from trial registries.

Conclusions

There is insufficient evidence regarding the clinical efficacy and safety of tocilizumab in patients with COVID-19. Its use should be considered experimental, requiring ethical approval and clinical trial oversight.

SUBMITTER: Cortegiani A 

PROVIDER: S-EPMC7369580 | biostudies-literature | 2021 Jan-Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review.

Cortegiani A A   Ippolito M M   Greco M M   Granone V V   Protti A A   Gregoretti C C   Giarratano A A   Einav S S   Cecconi M M  

Pulmonology 20200720 1


<h4>Background</h4>Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety.<h4>Methods</h4>MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 inf  ...[more]

Similar Datasets

| S-EPMC7652362 | biostudies-literature
| S-EPMC7377685 | biostudies-literature
| S-EPMC8127418 | biostudies-literature
| S-EPMC8128625 | biostudies-literature
| S-EPMC8420259 | biostudies-literature
| S-EPMC9978750 | biostudies-literature
| S-EPMC8127467 | biostudies-literature
| S-EPMC7405397 | biostudies-literature
| S-EPMC8584705 | biostudies-literature
| S-EPMC9555695 | biostudies-literature